Artrya AYA.AX · AUD

Its shares trade on ASX under the ticker AYA.AX. It has been listed since 26 November 2021. In the fiscal year to 30 June 2026, it reported revenue of A$28,000 and a net loss of A$25.2m. At that date it held total assets of A$85.3m and shareholders' equity of A$78.3m.

Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. The company is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The firm has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that empowers physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.

Figures and description from our data supplier, not checked against the company's own report.

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.